IL-17A Modulator Compounds Formula I

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack effective compounds to modulate IL-17A activity, which is implicated in various inflammatory, autoimmune, and cancer-related disorders, highlighting a need for novel therapeutic agents that can attenuate IL-17A activity.

Innovation Solution

Development of specific compounds, such as those defined by Formula I, which can modulate IL-17A activity by interacting with its receptor, thereby offering a therapeutic approach for treating diseases associated with IL-17A activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used, then existing treatment options are available, but they lack effective compounds to modulate IL-17A activity

Engineering Contradiction:

Improveeffectiveness of therapyVSAvoidability to modulate IL-17A activity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention segments the therapeutic approach by developing specific compound structures (Formula I) that selectively target the IL-17A pathway, separating this specific modulation capability from existing broad-spectrum immunosuppressants, thereby achieving reliable and effective IL-17A-specific therapy

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces small molecule compounds as intermediaries that bind to the IL-17A receptor or cytokine, mediating the therapeutic effect by blocking IL-17A signaling without requiring biologics or cell-based therapies, thus providing a new mechanism for modulating IL-17A activity

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If no specific IL-17A modulators exist, then current treatment options are limited, but developing new compounds increases therapeutic potential

Engineering Contradiction:

Improvetherapeutic options for IL-17A related diseasesVSAvoidavailability of proven therapeutic agents

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The invention applies parameter changes by optimizing the chemical structure parameters of compounds according to Formula I, including substituent groups R1-R6 and core structural elements, to achieve the desired balance between therapeutic potential and manufacturability through systematic structure-activity relationship studies

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20230227427A1Il-17a modulators

Publication Date: 2023.07.20 SANOFI SA(FR)

AI summary

The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.